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discouraged from joining by others (p<.001), not having an intrin- 
sic commitment to donate (p<.001), feeling encouraged by ones' 
culture or religion to join (p<.05), feeling like there are risks to 
donat ion (p<.01), and having a greater number  of medical 
(p<.001), and work and family concerns (p<.05) about donation - -  
were uniquely associated with higher levels of ambivalence after 
adjusting for the effects of other key indicators. We can conclude 
from these findings, that potential donors who are nmtivated by 
an intrinsic connnitment to donate, rather than extrinsic pressure, 
are less ambivalent about donating. In addition, recrnitment staff 
have a potentially critical role in reducing ambivalence among 
new recruits by providing information that may allay any unrealis- 
tic concerns recruits may have about the medical risks, and the 
impact of donation on work and family commitments. 
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T-CELL DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION 
FOLLOWED BY T CELL ADD-BACK IN PATIENTS WITH MULTIPLE 
MYELOMA 
Magalhaes-SilveJvna~l, M.; Lee, C.; Hohl, R.; Ritehie, J.; GiJzgrich, R. 
Interval MedMTze, University of Iowa, Iowa City, L~I. 
Allogeneic haematopoietic transplantation is potentially curative 
for patients (pts) with multiple myeloma. However, a high treat- 
ment-related mortality contributes to poor overall survival.An allo- 
geneic graft-versus-myeloma effect mediated by donor lymphocyte 
infusions has been demonstrated. Measures to minimize TRM while 
maintaining a graft-versus-host myeloma are needed.We valuated 
the outcome of 21 patients (pts) treated with a conditioning regimen 
comprising TBI  (1200cGY) ,  BCNU (300mg/m2), etoposide 
(1200rag/m2), ARA-C (6gin/m-') and cyclophosphamide (90mg/Kg) 
followed by T cell depleted bone marrow transplantation. Donor T 
cells were infused after transplantation ver a period of 2-3 months if 
acute GVHD gradec~ II was not seen. Cyclosporin was used for 
GVHD prophylaxis. Ten pts underwent transplantation using a sib- 
ling donor while 11 had an unrelated onor. There were 21 pts with 
a median age of 52 years (range 42-56); 14 were male and 7 female; 
median time from diagaaosis to transplantation was 16 months (range 
5-60); at diagnosis all pts had stage III disease; Ig type was igG in in 
12 pts, IgA in 5 and light chain in 4. Seventeen pts had sensitive dis- 
ease at time of transplantation. Twenty pts survived more than 21 
days and are evaluable for engraftment. The  median time to 
ANCc<0.5xl09/g was 14 days (range 12-30) and to a 
plateletc~25x10Q/L was 29 (range 12-70). Five pts died before day 
100. Cox proportional hazards models were used to identify factors 
associated with disease-free (DFS) and overall survival (OS). The risk 
factors considered : type of transplant( related vs unrelated), age ( 
<_50 vs~50), acute GVHD, chronic GVHD, disease sensitivity, gen- 
der, immunoglobulin type and T cell add-back. Univariate analysis 
demonstrated that gender (p=0.046) and T cell add-back (p=0.008) 
were predictive of OS. Type of transplant (p=0.047) and T cell add- 
back (p=0.005) were predictive of DFS. In a multivariate model type 
of transplant and T cell add-back were significantly associated with 
OS and DFS. The two year estimated OS and DFS for pts receiving 
T cell add-back is 50% and 40% respectively and for those not 
receiving T cell add-back is 9% and 0%. Our study demonstrates 
that T cell add-back after allogeneic T ceil depleted bone marrow 
transplantation induces ignificant graft-versus-myeloma effect. 
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ALLOGENEIC BONE MARROW TRANSPLANTATION FOR MYELOFIBRO- 
SIS DUE TO AGNOGENIC MYELOID METAPLASIA (AMM) AND ESSEN- 
TIAL THROMBOCYTOSIS (ET): EXPERIENCE OF TWO BONE MARROW 
TRANSPLANT CENTERS 
Daly, A.1; So~g, K.e; 3/les, mer, H.1; Liptm~, J.~; Hasegawa, ~V. ; Nevill, 
T.:; Toze, C.'-; Na*~tel, S.:; Hogge, D.2; Forrest, D."; Lavoie, j.e; 
&M)erlaud, It.2; Shepherd, ft.'-;ILiss, T5 l. Princess Margaret Hospital 
(PMH), Toronto, ON, Canada; 2. l, St*ecolmer General Hospital 
(UGH), Uan,:ozwer, BC, Cana&. 
Between August 1990 and June 2002, 25 patients with MF due 
to AMM (n=19) or ET  (n=6) underwent al loBMT at PMH or 
VGH.  The  median age at transplant was 48.7 ( Interquart i le 
range(IQR) 45.9-50.4) years, 18/25 were male and Lille risk 
groups at diagnosis were low (n=3), intermediate (n=13) and high 
(n=9) at diagnosis. Cytogenetics were abnormal in 8/19 cases test 
ed. Seven patients had previously undergone splenectomy and 
none of the patients had received induction therapy for leukemic 
transformation. Transplants took place a median of 10.7 (IQR 
5.67-26.5) months after diagnosis and median follow-up of surviv 
ing patients is 35 (IQR 21-61) months. Conditioning regimens 
were Cy/TBI (n=23) or Bu/Cy-2 (n=2), and all received CyA-Mtx 
for GVI ID  prophylaxis. Donors were matched (n=13) or mis- 
matched (n=2) relatives or matched unrelated volunteers (n=10). 
The median cell dose was 2.8 (IQR 1.88-3.78) xl0A8 MNC/kg. 
ANC > 500/btL and platelets > 20, 000/btL were observed in 22/22 
(median 25d.) and 17/22 (median 35d.) evaluable patients, respec- 
tively; median time to last RBC transfusion was 123 day's. Prior 
splenectomy was associated with more rapid neutrophil recovery 
(20 vs. 27.5 days, p=0.0019). Primary graft failure occurred in two 
cases, but both patients successfi~lly engrafted with a second trans- 
plant. Hepatic VOD occurred in 10 cases. Acute GVHD was 
grade II-IV in 13 and III IV in 4 cases. Chronic GVHD occurred 
in 10/17 evaluable patients. Eighteen patients had at least one 
bone marrow biopsy after transplantation. Median time to free- 
dora from fibrosis was 363d; at 18 months 84% of patients were 
free of fibrosis. A complete remission (defined as normalization of 
blood counts and absence of fibrosis and splenomegaly) occurred 
in 6 and CRP(as for CR with platelet count below normal) in 2 of 
18 cases with repeat biopsies. Median survival was 13.1 (IQR 3.6- 
33.8) months from BMT, 49.8 (IQR 17-66) months from diagno- 
sis. Kaplan-Meier estimate of 18-month overall survival was 
48.4%. Secondary engraftment failure occurred in one patient 
who died of GVHD on day 109. Non-re lapse mortal ity was 
observed in 10 cases and 4 patients died of progressive disease. We 
conclude that alloBMT offers a reasonable chance for resolution 
of MF, and may result in long-term disease-free survival. 
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THE OTTAWA IO-YEAR EXPERIENCE IN ALLOGENEIC STEM CELL 
TRANSPLANTATION FOR FOLLICULAR LYMPHOMA 
Sal, lofl~ M.S ; 3/lcDiar'mid, S/ ; Be~zce-Bruckler, I /  ; Atkins, H.2; Bredes- 
ou, C.s; Hopkins, H.Z; Genest, P.~-; Pe*'vy, G.2; Huebsch, b.lg. 1 
1. Ottawa Hospital, Ottawa, ON, CaTlada; 2. Ottawa Regio*~al Ca*lcer 
Cemre, Ottawa, ON, Canada, 3. Medical College of ~/iscousin, Mil- 
waukee, ~1~7. 
Allogeneic hematopoietic stem cell transplants (al lo-HSCT) 
have a number  of potent ia l  advantages over an autologous 
henaatopoietic stem cell transplant (AHSCT) in the treatment of 
follicular lymphoma (FL). We analyzed our experience in allo- 
HSCT for FL after establishing a program at our institution, 10 
years ago. Between April 1992 and September 1999, 19 patients 
with FL underwent an allo-HSCT. The median age was 41.7 (29- 
55) years. 8/19 were male. The  original diagnosis was FSCL 
(10/19), FML (4/19), FLCL (2/19) and 3/19 were transformed. 
5/10 had a previous AHSCT.  6/19 had received 1 pr ior 
chemotherapy, 9/19 had received 2 prior chemotherapies and 4/19 
had received >2 prior chemotherapies. 5/19 had received a prior 
AHSCT. 17/19 were transplanted from a related donor and 2 of 
these were syngeneic pairs. 13/17 who had a related donor 
received a CD34-selected marrow. The 2 syngeneic transplants 
used either unmanipulated marrow or PBSC. The remaining 2 
related al lo-HSCT received umnanipulated marrow. The condi- 
t ioning regimen in 14/19 was VP-16 (60 
mg/kg)/melphalan(14Omg/m2)/TBI(500 [13/19] or 1200 
[l/19]cGy). The remainder eceived BU/CY (4/19) or CY/TBI 
(1/!9). 12/19 received 1.25 mg/kg ATG. 13/19 received only 
cyclosporin for GVHD prophylaxis while 4/19 received bot[a 
cyclosporin and methotrexate and no GVHD prophylaxis was 
given to the syngeneic recipients. The  median follow-up and 
range has been 4.3 (0 - 8.9) years. The median time and range to 
neutrophil (>0.5x109/L) and platelet (>20x109/L) engraftment 
was 17 (11 - 30) and 22 (8 168) days, respectively. Acute GVHD 
was seen in 4/19 patients. 3/4 had grade 2 - 3 GVHD. 5/19 had 
chronic GVHD. 5/19 developed CMV detected in the blood and 
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were successfully treated with ganciclovir. 4/19 (21%) have 
relapsed and 6/19 (32%) have died (3 from relapse and 2 from 
TRM and 1 from aGVHD). 2/5 of those who died had a prior 
AHSCT. All deaths occurred within 22.4 months from the trans- 
plant. Those deaths related to TRM occurred within 1.2 months 
and the one death related to GVH occurred at 8.4 months from 
the transplant. The latest relapse occurred ahnost 2 years after the 
transplant. At 5 years the OS is 68% and the PFS is 63%. Our 
data are consistent with other investigators in the field and 
demonstrate hat an allo-HSC'I" appears to be feasible and may 
provide long-term remission in those who don't suffer from the 
early TRM. 
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BAYESIAN SENSITIVITY ANALYSES OF IO0-DAY SURVIVAL WITH 
INTRAVENOUS BUSULFAN VERSUS ALTERNATIVE MYELOABLATIVE 
CONDITIONING THERAPY IN ALLOGENEIC STEM CELL TRANS- 
PLANTATION (ALLO-SCT) FOR CHRONIC MYELOGENOUS 
LEUKEMIA (CML) 
Thall, P.F.; Champ/in, R.E.; A,dersso,, B.S. U.T. M.D. Anclet'son 
Ca1Jcev Cel~tet; Ho'.stoTz, 77(. 
Because the risk of death with allogeneie bone marrow trans- 
plantation (allotx) is ubstantial during the first 100 days, it is 
useful to compare different preparative r gimens in terms of the 
100-day survival probability. Based on data from 1812 CML 
patients who underwent allotx, we evaluated the 100-day mortal- 
ity rates of busulfan-based myeloablative conditioning therapy. 
47 patients received IV busulfan and cyclophosphamide (IV
BuCy2) with allo-SCT at M.D. Anderson Cancer Center 
(MDACC) during the period 1995-1999. The remaining 1765 
patients, whose data were supplied by the International Bone 
Marrow Transplant Registry (IBMTR), received various other 
conditioning regimens, primarily Cy-TBI (-45% of patients) or 
oral BuCy (~35%) in 1990-1998. In the registry no apparent dif- 
ference in early risk could be attributed to different conditioning 
regimens. A problem is that the IV-versus-alternative (treatment) 
effect of primary interest is confounded with a possible (center) 
effect arising from non-treatment differences between the 
MDACC and the IBMTR patients. That is, because the data do 
not  arise from a multi-center randomized trial, the treatment 
effect and center effect are confounded. Additional scientific 
complications are that 1) the IV-MDACC and alternative- 
IBMTR sample sizes are of very different magnitudes, 2) all 47 
IV-MDACC patients urvived 100 days, and 3) three different 
prognostic subgroups were involved (CP-AP-BC). We per- 
forlned Bayesian sensitivity analyses to assess the probability" that 
the IV-alternative treatment effect would favor 1V busulfan, both 
overall and within each prognostic group. The analyses compute 
the probability of a positive IV-versus-alternative tr atment 
effect for each of a range of possible center effect values. Using 
this method, the probability that IV BuCy is superior to the 
alternative treatments ranges from 0.54 to 0.99. A general con 
clusion is that, in terms of I00-day survival, either IV BuCy is 
superior to alternative myeloablative conditioning regimens for 
this indication or, alternatively, allo-SCT CML patients trans- 
planted at MDACC are much more likely to survive at least 100 
days than are patients treated at the other centers contributing to 
these data. 
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REPLACEMENT DONOR PROGRAM: THE DUTY TO PROTECT STEM CELL 
DONORS FROM MULTIPLE DONATIONS FOR DIFFERENT PATIENTS 
Gawellek, d.; Rail, G.; Rutt, C.; Baler, D.M. DKMS Deutsche 
Ka~ochemnarksloemte~vlatei, Taebillgen, BadeTz Hz'&v.temberg, Germany. 
Goal of the Replacement Donor Program is to provide an alter- 
native donor for the search centers in case that a donor has com- 
pleted a stem cell donation and is reserved for potential further 
donations for the same patient in a timeframe of actually 2 years. 
First intention is to provide a donor as long as possible for his 
patient afterwards the 2 year suspension. This would enable us to 
provide second or further stem cell donations if required for the 
one patient. Second intention is to protect he donor from 
requests for multiple patients. It could be observed several times 
that post-donation donors are of increased interest for the search 
centers and were requested for confirmatory t ping (CT) multiple 
times. Providing alternative donors would take off the burden 
from a single donor. Third intention is to fill up the gap in HLA- 
phenotypes when a donor is suspended from further donations 
within 2 years post-donation a d to increase the number of high 
resolution typed donors in our donor center. We think that donor 
centers like the DKMS have not only the duty but also the 
responsibility to protect heir donors from excessive demand by 
the search centers. To find a Replacement Donor we perform up 
to 100 DR intermediate r solution or up to 5 DR high resolution 
typings on our own behalf or each donor post donation. Own 
searches and typings are repeated till success as long as a reason- 
able chance remains to find a Replacement Donor. In October 
2002 over 27000 donors will be HLA-DR typed on medium or 
high resolution to provide a Replacement Donor for more then 
1100 donors. Out of these 27000 donors over 600 further equests 
(high resolution typing or confirmato W typing) and 38 donations 
could be observed and not a single stein cell donor donated again 
for another patient. 
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REGIMEN-RELATED TOXICITY (RRT) FOLLOWING REDUCED- 
INTENSITY HEMATOPOIETIC STEM-CELL TRANSPLANTATION 
(RIST): COMPARISON OF BEARMAN'S CRITERIA AND NCI-CTC VER- 
SION 20 
Imataki, 0.; Kami, M.; Saldwmla , M.; Kim, S.; Kojima, R.; Hori, A.; 
Mm:ashig~, 2X(; Makimoto, A.; Tanosaki, R.; Mi,  eishi, S.; Zakaue, Y. 
Hematopoietic Trnnsplantatimz U, it, ]x~atio,al Cmlcel" Create'r, Tokyo 
Ch~w-ku, Tokyo, Jap,m. 
Objective: The primary goal of this study was to evaluate the 
severity of RRT following RIST. The secondary goal was to 
compare value of Bearman's criteria and the National Cancer 
Institute-Common Toxicity Criteria (NCI-CTC) version 2.0 
for predicting the development of RRT after RIST. Methods: 
We reviewed the medical records of 86 patients who under- 
went RIST for the treatment of hematological diseases or solid 
tumors between September 1999 and April 2002. Preparative 
regimens included fludarabine 30 mg/m(2)/day or eladribine 
0.11 mg/m(2)/day on days -8 to -3 and busulfan 4 mg/kg/day 
on days -6 to -5, with or without anti-thymocyteglobulin. RRT 
was graded using two systems, Bearman's criteria and NCI- 
CTC version 2.0, from the day when conditioning regimens 
were initiated until 30 days after transplantation for 8 kinds of 
organ toxicity. Pulmonary toxicity, was re-graded on day 100. 
Comparison of prognostic influences between grade 0-1 RRT 
and grade 2-3 RRT by both Bearman's criteria and NCI-CTC 
was performed with Fisher exact tests. Overall survival of 
patients with each toxicity grade was compared with the 
Kaplan-Meier method and log-rank test. The Cox proportional 
hazards model was used for multivariate analysis. Results: In all 
organs, RRT had a tendency to be graded higher by Bearman's 
criteria and lower by NCI -CTC version 2.0. The highest 
grades, NCI-CTC grade 4 (p=0.003) and Bearman's grade 3 
(p<0.001), were significantly associated with the prognosis. 
Eleven of the 86 (12.8%) patients died of RRT, all of which 
had grade 3 by both Bearman's criteria and NCI-CTC. 4.7% 
(4/86) patients developed Bearman's grade 3 toxicity, two of 
whom died of RRT, whereas NCI-CTC grade 3 to 4 toxicity 
occurred in 50% (43/86) patients, 10 of which died of RRT. In 
a univariate and multivariate analysis of risk of survival, 
although any significant factors were not identified, there is a 
tendency of association with disease status and survival. Con- 
clusion: Since far less RRT was observed after RIST, com- 
pared to data reported after conventional HSCT, Bearman's 
criteria might not be sensitive nough to evaluate the RRT of 
preparative regimens and the ultimate prognosis, compared to 
NCI-CTC. 
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